Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. filed an 8-K reporting that it furnished a press release covering its financial and operating results for the quarter ended September 30, 2025, along with other corporate updates. The press release is provided as Exhibit 99.1.
The company’s securities listed on the NASDAQ Capital Market include common shares (ticker MDCX) and warrants (ticker MDCXW), with each warrant exercisable for one common share at an exercise price of $4.64 per share.
Medicus Pharma filed a prospectus supplement to its Form S-1 covering up to 3,710,000 common shares. The supplement attaches a Current Report on Form 8-K.
The 8-K details recent sales of 1,088,048 common shares to Yorkville under the Standby Equity Purchase Agreement, for approximate aggregate consideration of $2,526,364, across multiple issuances from September 8 to October 16, 2025. The company states it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma’s common shares trade on Nasdaq as MDCX; the last reported sales price was $2.41 on October 16, 2025. The company is an emerging growth company under SEC rules.
Medicus Pharma filed a prospectus supplement covering 2,260,000 common shares issuable upon the exercise of warrants. The company’s common shares and the public warrants (exercise price $4.64, expiring November 15, 2029) trade on Nasdaq as MDCX and MDCXW. On October 16, 2025, the last reported prices were $2.41 for the shares and $0.90 for the warrants.
Attached, a Current Report details recent sales under a Standby Equity Purchase Agreement with Yorkville. Between September 8 and October 16, 2025, the company sold 1,088,048 common shares to Yorkville for aggregate consideration of $2,526,364, in transactions exempt from registration under Section 4(a)(2). The company used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma Ltd. filed a prospectus supplement updating its S-1 to cover 1,115,500 common shares issuable upon the exercise of warrants. The supplement incorporates a new Form 8-K.
The company also reported under the SEPA with Yorkville that it sold 1,088,048 common shares across multiple dates for approximately $2,526,364 in aggregate consideration, and used part of the net proceeds to prepay a portion of a debenture with Yorkville. The common shares and public warrants trade on Nasdaq as MDCX and MDCXW; on October 16, 2025, last reported prices were $2.41 and $0.90, respectively. The public warrants have a $4.64 exercise price and expire on November 15, 2029.
Medicus Pharma Ltd. (MDCX) reported unregistered sales of 1,088,048 common shares for approximately $2,526,364 in aggregate consideration under its Standby Equity Purchase Agreement (SEPA) with Yorkville. The sales occurred between September 8 and October 16, 2025, at prices ranging from $1.7961 to $2.7698 per share.
The company stated it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville. The shares were issued in reliance on Section 4(a)(2) of the Securities Act. The SEPA permits additional share purchases by Yorkville from time to time, subject to its conditions and limitations, and Yorkville may resell purchased shares pursuant to an effective registration statement.
Medicus Pharma Ltd. has filed a Form S-1 to register the resale of up to 1,397,184 common shares by existing selling shareholders. These shares are part of the stock consideration issued in the August 2025 acquisition of Antev Limited, a late clinical-stage drug developer focused on the prostate cancer candidate Teverelix.
The company itself is not selling any securities in this offering and will receive no proceeds from any resale. After the offering, Medicus expects to have 21,865,288 common shares outstanding, based on 20,468,104 shares outstanding as of September 22, 2025. Medicus is an emerging growth and smaller reporting company, developing SkinJect for non-melanoma skin cancers and Teverelix for high-risk prostate cancer and acute urinary retention, and it highlights substantial risks, including a going concern warning and an accumulated deficit of about $40.2 million as of June 30, 2025.
Medicus Pharma Ltd. has filed a Form S-1 to register the resale of up to 1,397,184 common shares by existing selling shareholders. These shares are part of the stock consideration issued in the August 2025 acquisition of Antev Limited, a late clinical-stage drug developer focused on the prostate cancer candidate Teverelix.
The company itself is not selling any securities in this offering and will receive no proceeds from any resale. After the offering, Medicus expects to have 21,865,288 common shares outstanding, based on 20,468,104 shares outstanding as of September 22, 2025. Medicus is an emerging growth and smaller reporting company, developing SkinJect for non-melanoma skin cancers and Teverelix for high-risk prostate cancer and acute urinary retention, and it highlights substantial risks, including a going concern warning and an accumulated deficit of about $40.2 million as of June 30, 2025.
Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.
Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.
Medicus Pharma Ltd. filed an offering circular supplement dated September 18, 2025 registering 1,490,000 common shares issuable upon the exercise of outstanding warrants.
Concurrently, the company entered into a securities purchase agreement with YA II PN, Ltd. (Yorkville) for a $8,000,000 debenture. Net proceeds were approximately $5.7 million after satisfaction of an existing $1.7 million debt balance and fees. The Debenture bears interest at 8.00% per annum (increasing to 18.00% upon certain defaults), matures on September 17, 2026, and requires monthly repayments of $650,000 plus accrued interest beginning 45 days after issuance. Each subsidiary entered into a global guaranty in favor of Yorkville.
Medicus Pharma Ltd. entered into a new financing deal with YA II PN, Ltd. (Yorkville), issuing a debenture with a principal amount of $8,000,000. The company received approximately $5.7 million in net proceeds after using about $1.7 million to fully repay remaining debentures from a May 2025 financing and accounting for original issue discount and fees. The debenture carries 8.00% annual interest, which can increase to 18.00% if certain events of default occur, and matures on September 17, 2026. Medicus must make monthly payments of $650,000 plus accrued interest in cash starting 45 days after issuance, with any remaining balance due at maturity. All company subsidiaries entered into a global guaranty in favor of Yorkville, and the company may redeem the debenture early in cash, in whole or in part.
Medicus Pharma Ltd. filed an offering circular supplement covering 1,490,000 common shares issuable upon the exercise of its warrants. These public warrants have a $4.64 exercise price and expire on November 15, 2029, and trade on Nasdaq under the symbol MDCXW, while the common shares trade as MDCX.
The supplement attaches a current report describing leadership changes. Chief Financial Officer James Quinlan began a medical leave of absence on September 12, 2025, and President Carolyn Bonner was appointed Acting CFO without additional compensation. On September 11, 2025, the common shares and public warrants last traded at $2.41 and $0.76, respectively.